Insmed Incorporated (NASDAQ:INSM) Shares Purchased by Clearbridge Investments LLC

Clearbridge Investments LLC grew its stake in Insmed Incorporated (NASDAQ:INSM - Free Report) by 3.9% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 1,878,450 shares of the biopharmaceutical company's stock after acquiring an additional 69,683 shares during the quarter. Clearbridge Investments LLC owned about 1.05% of Insmed worth $129,688,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of INSM. Cerity Partners LLC increased its position in Insmed by 513.6% during the third quarter. Cerity Partners LLC now owns 21,348 shares of the biopharmaceutical company's stock worth $1,558,000 after purchasing an additional 17,869 shares during the last quarter. The Manufacturers Life Insurance Company grew its stake in shares of Insmed by 1.8% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 288,073 shares of the biopharmaceutical company's stock valued at $21,029,000 after buying an additional 5,062 shares during the period. Quantbot Technologies LP acquired a new stake in shares of Insmed during the 3rd quarter worth approximately $133,000. Zurcher Kantonalbank Zurich Cantonalbank raised its position in shares of Insmed by 7.3% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 36,721 shares of the biopharmaceutical company's stock valued at $2,681,000 after buying an additional 2,485 shares during the period. Finally, Captrust Financial Advisors lifted its holdings in Insmed by 40.9% in the third quarter. Captrust Financial Advisors now owns 6,280 shares of the biopharmaceutical company's stock valued at $458,000 after acquiring an additional 1,824 shares during the last quarter.

Insider Transactions at Insmed

In other Insmed news, insider Martina M.D. Flammer sold 6,172 shares of the firm's stock in a transaction that occurred on Friday, January 10th. The shares were sold at an average price of $63.64, for a total transaction of $392,786.08. Following the sale, the insider now owns 101,549 shares of the company's stock, valued at approximately $6,462,578.36. This trade represents a 5.73 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Orlov S. Nicole Schaeffer sold 91,140 shares of the business's stock in a transaction that occurred on Thursday, January 30th. The stock was sold at an average price of $80.00, for a total transaction of $7,291,200.00. Following the sale, the insider now owns 97,083 shares of the company's stock, valued at $7,766,640. This represents a 48.42 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 532,207 shares of company stock valued at $41,683,028. Insiders own 4.60% of the company's stock.

Insmed Stock Down 5.7 %

INSM stock traded down $4.15 during mid-day trading on Friday, reaching $69.18. The company had a trading volume of 3,123,325 shares, compared to its average volume of 2,234,367. Insmed Incorporated has a fifty-two week low of $21.92 and a fifty-two week high of $84.91. The company has a market capitalization of $12.52 billion, a price-to-earnings ratio of -12.38 and a beta of 1.28. The company has a debt-to-equity ratio of 2.03, a quick ratio of 5.99 and a current ratio of 6.37. The firm has a fifty day simple moving average of $77.78 and a 200 day simple moving average of $73.96.

Insmed (NASDAQ:INSM - Get Free Report) last issued its earnings results on Thursday, February 20th. The biopharmaceutical company reported ($1.32) earnings per share for the quarter, missing the consensus estimate of ($1.17) by ($0.15). Insmed had a negative net margin of 251.24% and a negative return on equity of 4,773.73%. The firm had revenue of $104.44 million during the quarter, compared to analyst estimates of $102.31 million. Analysts forecast that Insmed Incorporated will post -4.56 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts have commented on the company. Royal Bank of Canada restated an "outperform" rating and issued a $100.00 target price on shares of Insmed in a research report on Wednesday, March 19th. Truist Financial upped their target price on shares of Insmed from $105.00 to $108.00 and gave the company a "buy" rating in a research report on Friday, February 21st. Stifel Nicolaus dropped their price target on shares of Insmed from $97.00 to $96.00 and set a "buy" rating for the company in a research report on Friday, February 21st. Guggenheim restated a "buy" rating and issued a $101.00 price objective on shares of Insmed in a report on Tuesday, February 25th. Finally, JPMorgan Chase & Co. lifted their target price on shares of Insmed from $83.00 to $92.00 and gave the company an "overweight" rating in a report on Friday, February 7th. One analyst has rated the stock with a sell rating and sixteen have given a buy rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $94.00.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.